Core Insights - Cognition Therapeutics, Inc. reported positive results from the Phase 2 'SHINE' study of CT1812, showing cognitive improvement in participants treated for six months compared to placebo across various cognitive measures [1][9][12] - The study demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events being mild or moderate [10][12][18] - CT1812 showed significant changes in neurofilament light chain, a marker of neurodegeneration, particularly at the 300mg dose [2][12] Study Details - The SHINE study enrolled 153 adults with mild-to-moderate Alzheimer's disease, randomized to receive either placebo or one of two doses of CT1812 (100mg or 300mg) [18][22] - The primary endpoint was safety and tolerability, while the key secondary endpoint focused on cognitive measures, specifically ADAS-Cog 11 [22] - Participants in the placebo arm experienced a decline of approximately 2.70 points on ADAS-Cog 11, while those treated with CT1812 declined by an average of 1.66 points, indicating a 39% slowing of decline [18][22] Clinical Implications - The results suggest that CT1812 may serve as a monotherapy or in combination with approved drugs for treating Alzheimer's disease and related dementias [9][12] - The findings from the SHINE study will inform future clinical trials and dose selection for CT1812 [9][12][12] - The company is also conducting additional studies, including the SHIMMER trial for Lewy body dementia and the START trial for early-stage Alzheimer's disease [11][23] Safety Profile - The overall percentage of participants experiencing any adverse event was similar between CT1812 treatment arms (76.5%) and the placebo group (78%) [10][12] - Serious adverse events were reported in 6% of CT1812-treated participants compared to 10% in the placebo group [19] - Treatment-emergent liver function test (LFT) increases were observed in the 300mg group but subsided after drug cessation without serious liver injury [3][10] Future Outlook - The company is optimistic about the SHINE results and anticipates further insights from ongoing trials [11][12] - Cognition Therapeutics has received over $170 million in grant support from various institutions, aiding its research and development efforts [11] - The company aims to advance CT1812 in clinical trials targeting neurodegenerative diseases, leveraging the distinct mechanism of action of the σ-2 receptor [24]

The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial which enrolled 153 patients with mild-to-moderate Alzheimer's disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant ...

Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday. AAIC Presentation details 1. Abstract #95147: CSF Phosphoproteomics Biomarker An ...

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, ...

Core Insights - Cognition Therapeutics, Inc. announced that abstracts from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for presentation at the Alzheimer's Association's International Conference in Philadelphia from July 28-August 1, 2024 [1][2] Study Details - The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial enrolling approximately 144 patients with mild-to-moderate Alzheimer's disease, with participants randomized to receive either placebo or CT1812 at doses of 100 mg or 300 mg daily for six months [3] - The study endpoints include safety, cognitive function measured by the ADAS-Cog 11 scale, and biomarker evidence of disease modification, supported by approximately $30 million in grants from the National Institute on Aging [3] Drug Information - CT1812 is an experimental orally delivered small molecule that selectively binds to the sigma-2 receptor complex, displacing toxic Aβ oligomers, which are implicated in Alzheimer's disease progression [4] - The sigma-2 receptor complex is involved in regulating cellular processes that are damaged by toxic interactions with Aβ oligomers and oxidative stress, leading to cognitive impairment [4] Ongoing Studies - The company is currently recruiting participants for the START study of CT1812 in early Alzheimer's disease and the MAGNIFY study in adults with geographic atrophy due to dry age-related macular degeneration [5] - Enrollment has completed in the SHIMMER study of CT1812 in adults with dementia with Lewy bodies and the SHINE study [5] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [6] - The company is investigating CT1812 in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration, with a belief that targeting the sigma-2 receptor represents a distinct mechanism from other current treatment approaches [6]

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: "Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease." This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. Our podcast series does not constitute the practi ...

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: "Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease." This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. This conversation features a discussion of newly ...

17 The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Expected Volatility — Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a peri ...

Exhibit 99.1 Purchase, NY – May 7, 2024 – Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. Cash and cash equivalents as of March 31, 2024 were approximately $34.7 million and total grant funds remaining from the NIA were $62.3 million. Cash and cash equivalents includes net proce ...

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. "During t ...